SCHEMBL5367314

SCHEMBL5367314

CCc1ccc(-c2nc(CCOCC#CCSCC(=O)O)c(C)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
POLB P06746 2/20 0.47
PPARG P37231 10/20 0.46
PPARA Q07869 9/20 0.46
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
PPARD Q03181 3/20 0.44
TSHR P16473 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374332 0.93 RXFP1 (0.43) KDM4ERAB9AMAPTSMN1; SMN2PPARG
SCHEMBL5367857 0.91 PPARG (0.48) KDM4EMAPTSMN1; SMN2POLBPPARG
SCHEMBL5375744 0.91 MAPT (0.50) KDM4ERAB9AMAPTSMN1; SMN2POLB
SCHEMBL5377212 0.90 PPARG (0.53) KDM4EPPARGPPARAHPGDPPARD
SCHEMBL5368818 0.89 PPARG (0.53) KDM4EPPARGPPARAHPGDPPARD
SCHEMBL5370562 0.88 PPARG (0.42) KDM4EMAPTSMN1; SMN2POLBPPARG
SCHEMBL5365636 0.84 RXFP1 (0.46) KDM4EMAPTSMN1; SMN2POLBPPARG
SCHEMBL5373899 0.83 PPARG (0.41) PPARGPPARAPPARD
SCHEMBL5382125 0.83 PPARG (0.47) KDM4ERAB9AMAPTSMN1; SMN2POLB
SCHEMBL5377424 0.82 PPARG (0.48) KDM4EMAPTSMN1; SMN2PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US claimed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US claimed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP claimed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US disclosed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US disclosed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD KDM4E 2833/4885RAB9A 3543/4885MAPT 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.